Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials

Diabetes and Metabolism

Volumn 43, Issue 1, 2017, Pages 48-58

  Rehman, M B ^a   Tudrej, B V ^b   Soustre, J ^b   Buisson, M ^c   Archambault, P ^b   Pouchain, D ^d   Vaillant Roussel, H ^e,g   Gueyffier, F ^f   Faillie, J L ^c   Perault Pochat, M C ^a   Cornu, C ^c   Boussageon, R ^b  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b Faculty of Medicine   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ DE TOURS   (France)

^e UNIVERSITÉ CLERMONT AUVERGNE   (France)

^f UNIVERSITÉ LYON 1   (France)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

DPP 4 inhibitors; Meta analysis; Micro and macrovascular complications; Mortality; Randomized clinical trials; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ACUTE PANCREATITIS; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; MULTICENTER STUDY;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84994475820     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2016.09.005     Document Type: Article

References (28)

1. [1] Danaei, G., Finucane, M.M., Lu, Y., Singh, G.M., Cowan, M.J., Paciorek, C.J., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 378 (2011), 31–40.
2. [2] Wild, S., Roglic, G., Green, A., Sicree, R., King, H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004), 1047–1053.
3. [3] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
4. [4] Drucker, D.J., Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122 (2002), 531–544.
5. [5] Amori, R.E., Lau, J., Pittas, A.G., Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298 (2007), 194–206.
6. [6] Richter, B., Bandeira-Echtler, E., Bergerhoff, K., et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev, 2008, CD390067.
7. [7] Nissen, S.E., Wolski, K., Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
8. [8] U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008.
9. [9] Boussageon, R., Gueyffier, F., Cornu, C., Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?. Diabetes Metab 40 (2014), 169–175.
10. [10] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
11. [11] Higgins JPTAD, Sterne, J.A.C., Assessing risk of bias in included studies. Higgins, J.P.T., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions. Version 5.1.0, 2011, Cochrane collaboration.
12. [12] Scheen, A.J., Charbonnel, B., Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 40 (2014), 176–185.
13. [13] Elashoff, M., Matveyenko, A.V., Gier, B., Elashoff, R., Butler, P.C., Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies. Gastroenterology 141 (2011), 150–156.
14. [14] Egan, A.G., Blind, E., Dunder, K., de Graeff, P.A., Hummer, B.T., Bourcier, T., et al. Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med 370 (2014), 794–797.
15. [15] Gale, E.A., GLP-1 based agents and acute pancreatitis: drug safety falls victim to the three monkey paradigm. BMJ, 346, 2013, f1263, 10.1136/bmj.f1263.
16. [16] Monami, M., Dicembrini, I., Mannucci, E., Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 24 (2014), 689–697.
17. [17] Li, L., Li, S., Deng, K., Liu, J., Vandvik, P.O., Zhao, P., et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ, 352, 2016, i610, 10.1136/bmj.i610.
18. [18] Zannad, F., Cannon, C.P., Cushman, W.C., Bakris, G.L., Menon, V., Perez, A.T., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
19. [19] Udell, J.A., Cavender, M.A., Bhatt, D.L., Chatterjee, S., Farkouh, M.E., Scirica, B.M., Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 3 (2015 May), 356–366.
20. [20] Eurich, D.T., McAlister, F.A., Blackburn, D.F., Majumdar, S.R., Tsuyuki, R.T., Varney, J., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Brit Med J, 335(7618), 2007, 497.
21. [21] Kannel, W.B., Hjortland, M., Castelli, W.P., Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34 (1974), 29–34.
22. [22] Shindler, D.M., Kostis, J.B., Yusuf, S., Quinones, M.A., Pitt, B., Stewart, D., et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 77 (1996), 1017–1020.
23. [23] Iribarren, C., Karter, A.J., Go, A.S., Ferrara, A., Liu, J.Y., Sidney, S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 103 (2001), 2668–2673.
24. [24] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
25. [25] Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes (ADVANCE). N Engl J Med 358 (2008), 2560–2572.
26. [26] Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassaï, B., et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. Brit Med J, 343, 2011, d4169, 10.1136/bmj.d4169.
27. [27] Lincoff, A.M., Tardif, J.C., Schwartz, G.G., et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 311 (2014), 1515–1525.
28. [28] Bejan-Angoulvant, T., Cornu, C., Archambault, P., Tudrej, B., Audier, P., Brabant, Y., et al. Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?. Diabetes Metab 41 (2015), 195–201.